← Leaderboards
George Holland
Aviara Pharmaceuticals, Inc.
$813,803
Attributed
$2,293,047
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,293,047 · 2
By mechanism
R42$1,996,323 · 1
R41$296,724 · 1
Top collaborators
- Darren G Woodside3 shared
- Ronald J Biediger2 shared
Others in their field
Other Emerging Leaders on “Drug Candidate”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn$46,710,255
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
- Ryan Cirz · Revagenix, Inc.$22,711,751
- Alan D. Palkowitz · Indiana University Indianapolis$17,630,798
Research focus
Drug CandidateDysbiosisColitisDoseDrug KineticsDrug TargetingCell Adhesion MoleculesClinical TrialsCostCrohn&AposCellsAdrenal Cortex Hormones6-MercaptopurineBiologicalAffinityAdoptedAntibodiesChronicAzathioprineComplexAminosalicylateCaringBenefits And RisksEnvironmental Risk Factor
Grant awards (3)
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD$959,682
R42 · FY2024 · DK
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD$1,036,641
R42 · FY2023 · DK
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD$296,724
R41 · FY2020 · DK